Curcumin at the Nanoscale: Formulation Strategies and Mechanistic Advances for Cancer Therapy
Exon · 2026
DOI: 10.69936/en04y0026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Exon, 2026. Verfasst von Saad Ahmed und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Curcumin is a potent anticancer agent, however, its clinical effectiveness is limited by poor solubility, low bioavailability, and rapid metabolic degradation. Recent advances in nanotechnology have led to the development of carrier-free nanocurcumin (NC), a pure form of curcumin devoid of synthetic excipients, offering a high drug load and reduced toxicity. This review critically examines the emerging evidence supporting its role in cancer therapy. NC exhibits enhanced cellular uptake, triggers oxidative stress, and selectively activates mitochondrial apoptosis in tumor cells, thereby sparing healthy tissue. Moreover, they demonstrate synergy with chemotherapeutics by inhibiting pathways that contribute to the development of drug resistance. Unlike traditional formulations, this minimalist design bypasses the need for polymers or lipids, simplifying production and potentially improving safety profiles. However, despite promising preclinical data, progress is hindered by inconsistent fabrication methods, limited mechanistic insights, and a lack of translational studies. Bridging these gaps through standardization, in vivo validation, and regulatory alignment could unlock a new era for curcumin-based oncotherapeutics
Zitieren
APA
Ahmed, S., & Shabbir, A. (2026). Curcumin at the Nanoscale: Formulation Strategies and Mechanistic Advances for Cancer Therapy. Exon. https://doi.org/10.69936/en04y0026
Vancouver
Ahmed S, Shabbir A. Curcumin at the Nanoscale: Formulation Strategies and Mechanistic Advances for Cancer Therapy. Exon. 2026. doi:10.69936/en04y0026
BibTeX
@article{Ahmed2026,
author = {Ahmed, Saad and Shabbir, Aneela},
title = {Curcumin at the Nanoscale: Formulation Strategies and Mechanistic Advances for Cancer Therapy},
journal = {Exon},
year = {2026},
doi = {10.69936/en04y0026}
}
EUVIMED